Match Document Document Title
6864229 G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same  
The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.
6861058 Method for treating essential tremor with botulinum toxin type B  
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount...
6855727 Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect  
An antifatigue composition for reducing muscular fatigue or the like during or after exercise, which includes an imidazole compound obtained from extracts of fishes, shelifishes, fowl, flesh or...
6852690 Method and composition for enhanced parenteral nutrition  
A composition and method for improved parenteral administration of nutrients is provided. The method comprises co-administration of nutrients, especially carbohydrates, and an insulinotropic...
6841156 Method for treating muscle spasm with botulinum toxin type B  
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount...
6838431 Nutritional intervention composition containing a source of proteinase inhibitor extending post meal satiety  
The invention relates to a nutritional intervention composition in powder form that is taken before a meal and that extends post meal satiety. The compositions of the invention are comprised of at...
6838433 IL-6 antagonist peptides  
The present invention relates to IL-6 antagonist peptides, isolatable from a peptide library through the two-hybrids system by their ability to bind to the intracellular domain of gp130 and...
6833348 Intracellular glucocorticoid-induced leucine zippers modulators of apoptic cell death pathways  
A DNA sequence encoding a glucocorticoid-induced leucine-zipper family related protein (GILR), isoforms, fragments or analogs thereof said GILR, isoforms, fragments or analogs thereof capable of...
6815414 Pharmaceutical compositions for the treatment of helicobacter pylori-associated disorders  
The invention relates to pharmaceutical compositions and methods for treating and/or preventing Helicobacter pylori-associated disorders, particularly disorders of the gastrointestinal tract. The...
6780430 Stabilzation method of nano-sized emulsion using tocopheryl derivatives and external application for skin containing the same  
Disclosed herein is a stabilization method of nano-sized emulsion by using lecithin and tocopheryl derivatives represented by the following formula (I) and (Wherein,R1, R2 and R3 are H or methyl...
6767890 Peptides having anti-cancer and anti-inflammatory activity  
A pentapeptide is disclosed having the generic formula A-A-A-B-C (SEQ ID NO:2) wherein A is a non-polar amino acid, B is a polar amino acid, and C is a charged amino acid. In a preferred...
6747008 Methods for treating and preventing alopecia  
The present invention provides improved methods, kits, and pharmaceutical compositions for treating and preventing alopecia in a subject in need thereof by administering an effective amount of...
6733791 Sublingual compositions comprising thymosin fraction 5 and methods for administration thereof  
Methods and compositions are described which allow for the sublingual absorption of peptides by oral administration. A liquid and a tablet format for the sublingual approach are demonstrated. The...
6727226 Mu-conopeptides  
The present invention is to μ-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and...
6719977 Methods to potentiate cancer therapies  
Disclosed are methods for potentiating the anti-cancer properties of an anti-cancer therapy in a mammal by administering with the therapy a compound (such as relaxin or γ-IFN) that has a tissue...
6689747 Use of insulin for the treatment of cartilagenous disorders  
The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilagenous disorders, including arthritis, comprising the...
6689788 Method and composition for treatment of inflammatory bowel disease  
A composition in unit dosage form for the inhibition, prevention or treatment of inflammatory bowel disease comprising an effective amount of a compound having the formula: and a pharmaceutically...
6683054 Use of melagatran  
According to the invention there is provided the use of melagatran, or a pharmaceutically acceptable derivative or prodrug thereof, in the manufacture of a medicament for the treatment of...
6656466 Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition  
The present invention relates to novel process for the preparation of glycoproteins by mammalian cell culture wherein the sialic acid content of the glycoprotein produced is controlled over a...
6645496 Method for treating tardive dyskinesia with Botulinum toxin type B  
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount...
6645482 Proteoglycan compositions for treating arthritic inflammatory conditions  
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory...
6635625 Proteoglycan compositions for treating prostate and bladder inflammatory conditions  
Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory...
6632429 Methods for treating pervasive development disorders  
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and...
6630123 Method to enhance tissue accumulation of radiolabeled compounds  
Administration of a radioisotopic compound by infusion over a period of time greater than two hours, preferably greater than twelve hours, greatly increases the maximum radioactivity that...
6627603 Method for releasing an active principle contained a multiple emulsion  
A method for the controlled release of an active principle contained in a multiple water-in-oil-in-water emulsion characterized in that the multiple emulsion comprises an invert emulsion Ei with...
6627195 Binding agents to CD23  
The present invention relates to agents that bind CD23 and that can be used in the treatment of inflammatory, autoimmune or allergic diseases.
6616944 Self-assembling colloidal carriers for protein delivery  
The invention is directed to self-assembling, polymer-based delivery systems for proteins. The delivery systems comprises an active agent and a polyol ester of the invention, having a linear...
6605592 Protein HOFNF53  
The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. In particular, the present application...
6602519 Oxidized thymosin β4  
The present invention relates to the use of oxidized thymosin β4 in therapy, more particularly in the treatment of diseases or conditions associated with an inflammatory response of septic shock.
6602849 Cyclic somatostatin analogs  
The present invention is directed to cyclic derivatives containing an imidazole cis amide bond mimetic which bind selectively to somatostatin receptor subtypes and the use thereof in treating...
6573241 Therapeutic agent for the suppression of snoring noises  
In a method of manufacturing a therapeutic agent to be administered intramuscularly for suppressing snoring noises a high-purity Clostridium toxin BoNT/A or TeNT or at least one of a high-purity...
6565879 Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers  
A method is provided for increasing the permeability of skin or mucosal tissue to a topically or transdermally administered pharmacologically or cosmeceutically active peptide, polypeptide or...
6566338 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death  
The use of caspase inhibitors for treating, ameliorating, and preventing non-cancer cell death during chemotherapy and radiation therapy and for treating and ameliorating the side effects of...
6559119 Method of preparing a tissue sealant-treated biomedical material  
This invention provides methods for the preparation of a tissue sealant-treated biomaterial, wherein the tissue sealant used in the method comprises at least one composition which is selected from...
6548066 Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors  
The invention concerns immunogens, immunogenic compositions and method for the treatment of gastrin-dependent tumors. The immunogens comprise a peptide from the CCK-B/gastrin-receptor conjugated...
6548527 Treatments for immune-mediated ear disorders  
Disclosed herein are methods for treating immune-mediated ear disorders, such as IMCVDs, or their symptoms, involving administration of a therapeutically-effective amount of a TNF antagonist, such...
6541037 Delivery vehicle  
The present invention provides delivery vehicles comprising a synthetic, poorly crystalline apatite (PCA) calcium phosphate and a biologically active agent. The PCA calcium phosphate offers many...
6534084 Porous tissue scaffoldings for the repair or regeneration of tissue  
The present patent describes a three-dimensional inter-connected open cell porous foams that have a gradient in composition and/or microstructure through one or more directions. These foams can be...
6514939 Atrial natriuretic factor mutants and ischemic stroke  
The present invention is based upon the observation that a mutant atrial natriuretic factor (ANF) gene increases stroke latency in spontaneously hypertensive rats-stroke prone (SHRSP)....
6497877 Plasminogen activator as an anti-inflammatory agent  
Plasminogen activator acts as an anti-inflammatory agent by inhibiting generation of superoxide anion by a mechanism that is not related to L-arginine, is not dependent on thrombolytic activity,...
6495521 Combination therapy method for treating chronic hepatitis B  
The present invention is aimed at augmenting the success rate of using thymosin in treatment of chronic hepatitis B, by employing a combination therapy using thymosin with antiviral agents which...
6468977 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes  
Novel 1,2,4-thiadiazole compounds are provided, which are effective as inhibitors of cysteine activity-dependent enzymes and in particular of cysteine proteases. The compounds are useful in...
6464987 Pharmaceutical compositions capable of being gelled  
A fluid pharmaceutical composition is described which allows the controlled release of at least one active substance. The composition comprises a therapeutically effective amount of at least one...
6462020 Small peptides and methods for treatment of asthma and inflammation  
A pharmaceutical composition is described as an admixture of a pharmacological carrier and a peptide having the formula f-Met-Leu-X. X is selected from the group consisting of Tyr, Tyr-Phe,...
6458365 Method for treating headache  
A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount...
6451760 Treatment of inflammation using a 2F1 polypeptide or an antibody thereto  
2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting...
6444639 HCG and derivatives as matrix metalloproteases inhibitors  
The use of hCG, hCG β-subunit, as well as fragments and active derivatives thereof, or hCG β-core in the preparation of a medicament for the prophylaxis and/or the treatment of pathologies...
6429190 Method for extending the satiety of food by adding a nutritional composition designed to stimulate cholecystokinin(CCK)  
A nutritional composition for adding to food for enhancing and extending the satiety of the food by stimulating CCK levels in a calorically efficient manner and for reducing weight. The...
6423680 Inhibitor of platelet activating factor  
An anti-inflammatory composition is provided. The composition comprises GM2 activator protein or a peptide derived from the GM2 activator protein which is capable of inhibiting platelet activating...
6419929 Recombinant RANK-L polypeptide  
Isolated recombinant RANK-L polypeptide DNAs encoding RANK-L polypeptide, and pharmaceutical compositions made therefrom, are disclosed. The isolated RANK-L polypeptide can be used to regulate an...